| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697545 | Cancer Treatment Reviews | 2017 | 6 Pages |
Abstract
Our data strongly suggest that cost-analyses should be carefully evaluated in the coming years, in particular in patients with HER2-negative tumors.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Francesca Tartari, Matteo Santoni, Mirco Pistelli, Rossana Berardi,